Dec 24 (Reuters) - Shares of Agios Pharmaceuticals (AGIO) jumped 18% on Wednesday after the U.S. Food and Drug Administration approved the expanded use of its drug for the treatment of a type of blood disorder.
The drug mitapivat is now approved as a treatment for patients with anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia, the company said late on Tuesday.
Thalassemia is an inherited blood disorder affecting the body's ability to produce hemoglobin and healthy red blood cells.
The drug, under the brand name Aqvesme, is expected to be available in late January next year, following the implementation of the required safety program.
Mitapivat was already approved by the U.S. FDA in 2022 to treat low red blood cell counts in adults with pyruvate kinase deficiency, under the brand name of Pyrukynd.
"The approval unlocks an additional $320 million in peak revenue opportunity layered atop the existing mitapivat franchise," Truist analyst Gregory Renza said.
The latest approval is based on a late-stage study in which patients receiving mitapivat showed a statistically significant increase in hemoglobin response compared to those on placebo.
Aqvesme will carry a boxed warning for liver function tests every four weeks during the first 24 weeks of treatment and advises against use in patients with cirrhosis, Renza added.
(Reporting by Siddhi Mahatole in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
Discovery of ancient pleasure boat reveals Egypt's maritime history - 2Novo Nordisk justifies reasoning behind failed GLP-1 Alzheimer's trials
- 3Rocket Lab launches mystery satellite for 'confidential commercial customer' (video)
- 4Congo declares its latest Ebola outbreak over, after 43 deaths
- 5Independence from the rat race: How to Save and Contribute Shrewdly
- Vote In favor of Your Favored Language Learning Applications
- Step by step instructions to Protect Your Retirement with Senior Protection.
- Exclusive new photos from 'Michael' biopic show Jaafar Jackson as King of Pop
- Insight: Pills, TikTok, weight-loss apps and the consumer-driven future of GLP-1s
- Monetary Security: Building Serious areas of strength for an Establishment
- NMG signs new graphite supply deal with Canadian Government
- Israel kidnaps PIJ terrorist in covert op. in Hamas-controlled Gaza in pursuit of Ran Gvili
- German foreign minister heads to China to talk rare-earth exports
- How to see the Ursids, the final meteor shower of 2025
